Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Goldkind

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Cureus|October 28, 2024
Hidden in Plain Sight: Pancreatic and Gastric Metastases of Renal Cell Carcinoma Undetectable on ImagingMadison B Peregoy, Charleston R Powell, Lawrence Goldkind, et al.
The American Journal of Gastroenterology|January 29, 2009
How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trialLoren Laine, Lawrence Goldkind, Sean P Curtis, et al.
Nature Communications|September 18, 2021
A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetesStephen A Harrison, Nadege Gunn, Guy W Neff, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Cureus|October 28, 2024
Hidden in Plain Sight: Pancreatic and Gastric Metastases of Renal Cell Carcinoma Undetectable on ImagingMadison B Peregoy, Charleston R Powell, Lawrence Goldkind, et al.
The American Journal of Gastroenterology|January 29, 2009
How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trialLoren Laine, Lawrence Goldkind, Sean P Curtis, et al.
Nature Communications|September 18, 2021
A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetesStephen A Harrison, Nadege Gunn, Guy W Neff, et al.
Pageof 2